Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mark Daniel Pegram, MD and Julie R. Gralow, MD, on Thursday, October 15, 2020 at 8:00 PM PDT.

Considerations in Metastatic HER2+ Breast Cancer

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP, on Wednesday, October 7, 2020 at 8 PM EDT.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Hope Rugo, MD and Sara Hurvitz, MD on Wednesday, October 7, 2020 at 7:30 PM PDT.

In this Onclive® webinar, leading lymphoma experts will discuss the use of new and emerging treatment options for relapsed/refractory diffuse large B-cell lymphoma and how these treatments can help shape individualized treatment plans. Join us Tuesday, September 15, 2020 at 8 PM EDT.

A New Chapter in DLBCL: Uncovering New Treatment Options For Your Patients

In this Onclive® webinar, leading experts will highlight how the field in HER2+ breast cancer is evolving and hear direct from leading experts. Join us Tuesday, September 15, 2020 at 8 PM EST.

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mohammad Jahanzed, MD, FACP, FASCO, and Reshma L. Mahtani, DO, on Monday, October 26, 2020 at 8 PM EDT.

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

During this live broadcast, you'll learn about XPOVIO® (selinexor), including an overview of:

Michael W. Schuster, MD, and Hakan Kaya, MD

Join Us to Learn About XPOVIO

Join us for a presentation on an FDA-approved treatment option to better treat your patients with advanced cutaneous squamous cell carcinoma 

on Thursday, November 5, 2020 at 7:00 PM EDT.

An FDA-approved treatment option in patients with Advanced Cutaneous Squamous Cell Carcinoma

We are pleased to announce the Eighth Annual Giants of Cancer Care

 class of inductees. Join us to honor these 15 individuals for their unmatched genius, their generous compassion, and the countless hours of work they have sacrificed to help their patients.

Webinars